Meliora Therapeutics builds a machine-learning-driven computational platform to decipher oncology drugs' true mechanisms of action and create an industry-first MOA atlas. Its core product is an inference engine that uses "molecular fingerprints" for tens of thousands of small molecules to match compounds to mechanisms. The company has a computational prototype and has generated in‑vitro wet lab data validating dozens of compounds computationally identified as having alternate MOAs, with many showing strong potency against predicted targets. Meliora plans to expand its platform, build a proprietary data moat, select mischaracterized scaffolds as starting points for lead precision therapeutic programs, and grow its team, operations, and industry partnerships. The company was founded in September 2021 and is headquartered in Menlo Park, CA. It recently closed a seed financing to accelerate development of its proprietary platform and programs.

Total raised

$11M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2022